Polaryx Therapeutics, Inc. Common Stock
Support and Resistance Levels
Past performance
News About PLYX
All events for PLYX
All deals for PLYX
Financial Ratios
Financial Statements
PLYX vs Sector & Peers
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey. Website polaryx.com
Headquarters Paramus, NJ, US